US Patent

US10925829 — Stable solid fingolimod dosage forms

Formulation · Assigned to Handa Neuroscience LLC · Expires 2036-01-19 · 10y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects stable solid pharmaceutical dosage forms of fingolimod or its salts, conjugates, or complexes.

USPTO Abstract

The present invention relates to a solid pharmaceutical dosage forms and methods for preparing the solid pharmaceutical dosage form that contains fingolimod or its pharmaceutically acceptable salts, conjugates or complexes thereof. The solid pharmaceutical dosage forms may rapidly disintegrate in a patient's oral cavity.

Drugs covered by this patent

fingolimod-lauryl-sulfate (FINGOLIMOD LAURYL SULFATE)

Patent Metadata

Patent number: US10925829
Jurisdiction: US
Classification: Formulation
Expires: 2036-01-19
Drug substance claim: No
Drug product claim: Yes
Assignee: Handa Neuroscience LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.